U.S. Markets closed

icad Inc (ICAD) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

icad Inc (ICAD) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. icad Inc is a provider of image analysis, work flow solutions and radiation therapy for early identification and treatment of cancer. The company has cancer detection and cancer therapy segments. icad Inc has a market cap of $89.170 million; its shares were traded at around $5.17 with and P/S ratio of 3.38.

For the last quarter icad Inc reported a revenue of $6.95 million, compared with the revenue of $7.90 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $25.6 million, a decrease of 8.8% from the previous year. For the last five years icad Inc had an average revenue decline of 8.4% a year.

The reported loss per diluted share was 54 cents for the year, compared with the loss per share of $0.07 in the previous year. The icad Inc had an operating margin of -31.73%, compared with the operating margin of -35.52% a year before. The 10-year historical median operating margin of icad Inc is -22.88%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, icad Inc has the cash and cash equivalents of $12.2 million, compared with $9.39 million in the previous year. The long term debt was $11.2 million, compared with $5.15 million in the previous year. icad Inc has a financial strength rank of 3 (out of 10).

At the current stock price of $5.17, icad Inc is traded at 51.6% premium to its historical median P/S valuation band of $3.41. The P/S ratio of the stock is 3.38, while the historical median P/S ratio is 2.22. The stock gained 53.70% during the past 12 months.

For the complete 20-year historical financial data of ICAD, click here.

This article first appeared on GuruFocus.